While the volume of regulatory data is above this point last year by more than 17%, the proportion of COVID-19-related news is nearly the same, as is the number of U.S.-approved new molecular entities (NMEs).
A look at the COVID-19 cases and deaths globally and on a weekly basis suggest that the world is not doing any better than it was this time last year, even though numerous vaccines are now authorized and approved.